|
Synonyms: 16B5 [1] | AB-16B5 | AB-sCLU mAb | AB16B5
Compound class:
Antibody
Comment: Sotevtamab (AB-16B5) is a humanized IgG2 antibody against secreted clusterin. It was developed by Alethia Biotherapeutics for anti-cancer potential. Peptide sequences of the heavy and light chains of the antibody are claimed in patent WO2011063523A1 [1], via which sotevtamab can be linked to the antibody designated as humanised 16B5. Sotevtamab is expected to inhibit clusterin-induced epithelial to mesenchymal transition, as a mechanism to both reduce tumour invasion and augment the response to standard of care chemotherapy.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Sotevtamab (AB-16B5) has progressed to clinical evaluation in advanced solid tumours. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02412462 | Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy | Phase 1 Interventional | Alethia Biotherapeutics | ||
| NCT04364620 | AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) | Phase 2 Interventional | Alethia Biotherapeutics | ||
